A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease

J Neuropsychiatry Clin Neurosci. 1996 Summer;8(3):270-5. doi: 10.1176/jnp.8.3.270.


Twenty-one depressed patients with probable Alzheimer's disease (AD) were randomized to receive a 6-week treatment with clomipramine or placebo in a study with a double-blind crossover design. Main outcome measures were Hamilton Depression, Mini-Mental State (MMSE), and Functional Independence Measure (FIM) scores. Mood improved significantly on both clomipramine and placebo, but clomipramine was significantly more effective than placebo during the first 6-week treatment period. Patients started on clomipramine maintained improvement during the washout and placebo periods, whereas patients started on placebo worsened during the washout period. However, patients on clomipramine showed significantly lower MMSE scores overall than patients on placebo. No significant drug effects were found on FIM scores. Clomipramine proved to be a useful treatment of depression in patients with probable AD.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activities of Daily Living
  • Aged
  • Alzheimer Disease / complications
  • Alzheimer Disease / psychology*
  • Antidepressive Agents, Tricyclic / adverse effects
  • Antidepressive Agents, Tricyclic / therapeutic use*
  • Clomipramine / adverse effects
  • Clomipramine / therapeutic use*
  • Cognition Disorders / drug therapy
  • Cognition Disorders / psychology
  • Cross-Over Studies
  • Depressive Disorder / complications
  • Depressive Disorder / drug therapy*
  • Depressive Disorder / psychology
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Psychiatric Status Rating Scales


  • Antidepressive Agents, Tricyclic
  • Clomipramine